MESO

Mesoblast (MESO)

Mesoblast Limited

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:MESO

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/04/30	10 : 05	GlobeNewswire Inc.	Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024	NASDAQ:MESO	Mesoblast Limited
2024/03/26	22 : 25	AllPennyStocks.com	FDA Commentary Sends Biotech Soaring During Premarket Hours	NASDAQ:MESO	Mesoblast Limited
2024/03/26	11 : 34	GlobeNewswire Inc.	United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)	NASDAQ:MESO	Mesoblast Limited
2024/03/14	08 : 30	GlobeNewswire Inc.	Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer	NASDAQ:MESO	Mesoblast Limited
2024/03/11	08 : 54	GlobeNewswire Inc.	United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)	NASDAQ:MESO	Mesoblast Limited
2024/02/29	07 : 57	GlobeNewswire Inc.	Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023	NASDAQ:MESO	Mesoblast Limited
2024/02/26	21 : 00	GlobeNewswire Inc.	Mesoblast Financial Results and Corporate Update Webcast	NASDAQ:MESO	Mesoblast Limited
2024/02/15	09 : 46	GlobeNewswire Inc.	United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease	NASDAQ:MESO	Mesoblast Limited
2024/02/01	11 : 34	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MESO	Mesoblast Limited
2024/01/31	11 : 13	GlobeNewswire Inc.	Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023	NASDAQ:MESO	Mesoblast Limited
2024/01/19	09 : 28	Dow Jones News	Mesoblast Gets FDA's Special Pediatric Designation for Revascor Heart Treatment	NASDAQ:MESO	Mesoblast Limited
2024/01/19	08 : 36	GlobeNewswire Inc.	United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease	NASDAQ:MESO	Mesoblast Limited
2024/01/16	20 : 33	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:MESO	Mesoblast Limited
2024/01/05	11 : 57	Edgar (US Regulatory)	Form F-6 POS - Post-effective amendments for immediately effective filing	NASDAQ:MESO	Mesoblast Limited
2023/12/23	07 : 13	Edgar (US Regulatory)	Form F-6 POS - Post-effective amendments for immediately effective filing	NASDAQ:MESO	Mesoblast Limited
2023/11/27	08 : 56	GlobeNewswire Inc.	Mesoblast Files for Orphan Drug and Pediatric Rare Disease Designations for Rexlemestrocel-L as Treatment for Severe Congenital Heart Disease	NASDAQ:MESO	Mesoblast Limited
2023/11/23	03 : 35	AllPennyStocks.com	Biotech Shares Soar Following Major Announcement	NASDAQ:MESO	Mesoblast Limited
2023/11/23	03 : 35	AllPennyStocks.com	Biotech Shares Soar Following Major Announcement	NASDAQ:MESO	Mesoblast Limited
2023/11/22	08 : 32	GlobeNewswire Inc.	Mesoblast Partners With Blood and Marrow Transplant Clinical Trials Network (BMT CTN) on Pivotal Trial in Adults With SR-aGVHD	NASDAQ:MESO	Mesoblast Limited
2023/10/31	09 : 04	GlobeNewswire Inc.	Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2023	NASDAQ:MESO	Mesoblast Limited
2023/09/26	19 : 18	GlobeNewswire Inc.	Jane Bell AM Appointed Chair of Mesoblast Audit and Risk Committee	NASDAQ:MESO	Mesoblast Limited
2023/09/21	16 : 30	GlobeNewswire Inc.	Key Outcomes From FDA Type A Meeting and Mesoblast Next Steps to Achieve RYONCIL Approval	NASDAQ:MESO	Mesoblast Limited
2023/09/06	19 : 42	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:MESO	Mesoblast Limited
2023/08/31	08 : 07	GlobeNewswire Inc.	Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2023	NASDAQ:MESO	Mesoblast Limited
2023/08/29	20 : 00	GlobeNewswire Inc.	Mesoblast Financial Results and Corporate Update Webcast	NASDAQ:MESO	Mesoblast Limited
2023/08/04	22 : 03	Dow Jones News	Mesoblast ADSs Plunge Premarket on Latest FDA Rejection	NASDAQ:MESO	Mesoblast Limited
2023/08/04	09 : 10	GlobeNewswire Inc.	Mesoblast Receives Complete Response From U.S. Food and Drug Administration for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in Children	NASDAQ:MESO	Mesoblast Limited
2023/07/31	09 : 31	GlobeNewswire Inc.	Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2023	NASDAQ:MESO	Mesoblast Limited
2023/06/06	21 : 46	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:MESO	Mesoblast Limited
2023/06/05	09 : 21	GlobeNewswire Inc.	Mesoblast Director Philip R. Krause, M.D., Appointed to Strategic Advisory Role	NASDAQ:MESO	Mesoblast Limited